Navigation Links
Sorrento Therapeutics Announces Pricing of Public Offering of 4,150,000 Shares of Common Stock and Listing on NASDAQ
Date:10/24/2013

SAN DIEGO, Oct. 24, 2013 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE) announced the pricing of an underwritten public offering of 4,150,000 shares of common stock at an offering price of $7.25 per share.  The shares will begin trading on The NASDAQ Capital Market on October 25, 2013 under the symbol "SRNE." The gross proceeds to Sorrento from this offering are expected to be approximately $30 million, before deducting underwriting discounts and commissions and other estimated offering expenses. The offering is expected to close on or about October 30, 2013, subject to customary closing conditions. Sorrento has granted the underwriters a 45-day option to purchase up to an additional 622,500 shares of common stock to cover over-allotments, if any.

Sorrento intends to use the net proceeds received from the offering to fund its research and development activities, including its registrational clinical trial of Cynviloq™, for working capital, other general corporate purposes, and possibly acquisitions of other companies, products or technologies.

In connection with its listing on The NASDAQ Capital Market, Sorrento's common stock will cease trading on the OTC QB.   

Aegis Capital Corp. is acting as the sole book-running manager for this offering.

CRT Capital is acting as co-manager for this offering. 

A shelf registration statement and accompanying base prospectus on Form S-3 relating to the shares was filed with the Securities and Exchange Commission and is effective.  A preliminary prospectus supplement relating to the offering has been filed with the SEC and is available on the SEC's web site at http://www.sec.gov. Copies of the final prospectus supplement, when available, may be obtained from the SEC's web site or the offices of Aegis C
'/>"/>

SOURCE Sorrento Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Sorrento Therapeutics Secures Rights to Biomiga Diagnostics Therapeutic Drug Monitoring Device for Development of Personalized Paclitaxel Cancer Therapy
2. Sorrento Therapeutics Completes IgDraSol Merger
3. Sorrento Therapeutics to Present at Two Healthcare Conferences
4. Sorrento Therapeutics and Ben-Gurion University Sign an Agreement for the Development of Anti-Hepatitis C Virus Antibodies
5. Sorrento Therapeutics and IGDRASOL to Present Late Stage Clinical Data Updates on their Oncology Nanomedicine Platform at the Joint Meeting of the European Foundation for Clinical Nanomedicine and European Technology Platform on Nanomedicine in Base
6. Sorrento Therapeutics Receives Frost & Sullivans Prestigious 2013 Global Investment Opportunity Award in the Oncology Market
7. Sorrento Therapeutics Receives Frost & Sullivans 2013 Global Investment Opportunity Award in Oncology
8. Sorrento Therapeutics to Present at the Jefferies 2013 Global Healthcare Conference in New York City
9. Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases
10. Sorrento Therapeutics, Inc. and IGDRASOL Announce Presentation on Non-Biologic Nanoparticle paclitaxel (NBN-Pac) Formulations for the Treatment of Solid Tumors at the Nanomedicine 2013 Meeting in Barcelona, Spain
11. Sorrento Therapeutics Signs Exclusive Option to Acquire IGDRASOL
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... 2015 Dynatronics Corporation (NASDAQ: DYNT ) today ... to the Company,s Board of Directors effective March 23, 2015, ... 2014 of board member Joseph Barton .  ... Board of Directors represents an important step forward for the ... of Dynatronics.  "Rich is a proven leader and is well-known ...
(Date:3/27/2015)... 27, 2015 The Temple Health & Bioscience District ... 5,000-square-foot building at 1802 South First St. in the Temple ... the City of Temple to receive ... the Central Texas Veterans Health Care System, the new facility ... early stage biotechnology and life science companies. ...
(Date:3/27/2015)... 2015 XRpro Sciences, Inc., a provider ... development services which features high throughput transporter and ... financial results for the year ended December 31, ... of XRpro Sciences commented, "We have completed a ... stage to commercial stage in large part by ...
Breaking Medicine Technology:Dynatronics Announces Appointment of Richard J. Linder to Board of Directors 2Temple Health & Bioscience District Relocates, Offers Office And Lab Space To Biotech Companies 2XRpro Sciences Announces Fiscal 2014 Financial Results 2XRpro Sciences Announces Fiscal 2014 Financial Results 3XRpro Sciences Announces Fiscal 2014 Financial Results 4
... 21, 2011 VIVUS, Inc. (Nasdaq: VVUS ) ... Food and Drug Administration (FDA) for the New Drug Application ... obesity.  The meeting occurred on January 19th at the FDA,s ... the FDA and VIVUS, management and consultants.  At this meeting ...
... held) today announced that they have signed a multi-year ... clear, and manufacture assays for the Abbott Molecular FDA ... terms have not been disclosed. IMDx ... evolving clinical needs. The tests are designed utilizing IMDx,s ...
Cached Medicine Technology:VIVUS Provides Regulatory Update on QNEXA NDA 2VIVUS Provides Regulatory Update on QNEXA NDA 3Intelligent Medical Devices, Inc. (IMDx) Enters into an Agreement with Abbott for the Distribution of a Broad Menu of Molecular Tests 2
(Date:3/27/2015)... The federal court overseeing thousands of ... medication increases the risk that a patient will develop ... Dismiss four individual cases that had been filed in ... in the U.S. District Court, District of South Carolina, ... were warranted because the plaintiffs in those claims had ...
(Date:3/27/2015)... Kansas City, Mo (PRWEB) March 27, 2015 ... common complications for patients undergoing percutaneous coronary intervention ... Ironically, studies have observed a “risk-treatment paradox,” in ... to gain from treatment are treated less often ... , Researchers at Saint Luke’s Mid America Heart ...
(Date:3/27/2015)... Healthpointe is proud to announce that ... now treating knee and hip joint disorders in practice ... Beach, and La Mirada. Dr. Stanley Katz specializes in ... joint disorders as well as chronic conditions such as ... his patients back to their normal lives. Many ...
(Date:3/27/2015)... Ticket Down is a reputable source for authentic ... After a phenomenal and highly successful live tour last year, the ... on tour again in 2015 and they will be visiting 8 ... 29th in New York City at the cozy Beacon Theatre and ... May 10th. , Fans of the hit show can look forward ...
(Date:3/27/2015)... Jose, CA (PRWEB) March 27, 2015 While ... week’s 2015 GPU technology conference (GTC) , the CEO ... fight cancer and push the human lifespan well beyond the ... MD informatics company , is one of 12 companies ... , While other startups in the GTC Emerging Companies ...
Breaking Medicine News(10 mins):Health News:Lipitor Lawsuits Move Forward in Federal Multidistrict Litigation, as Court Rules on Pfizer’s Motion to Dismiss Certain Cases 2Health News:Lipitor Lawsuits Move Forward in Federal Multidistrict Litigation, as Court Rules on Pfizer’s Motion to Dismiss Certain Cases 3Health News:Precision Medicine Improves Use of Bleeding Avoidance Strategies and Reduces Bleeding in Patients Undergoing Percutaneous Coronary Intervention 2Health News:Precision Medicine Improves Use of Bleeding Avoidance Strategies and Reduces Bleeding in Patients Undergoing Percutaneous Coronary Intervention 3Health News:Fellowship-Trained and Board-Certified Orthopedic Surgeon is Now Treating Knee and Hip Joint Disorders in Anaheim, California 2Health News:Fellowship-Trained and Board-Certified Orthopedic Surgeon is Now Treating Knee and Hip Joint Disorders in Anaheim, California 3Health News:Nashville Live in Concert Tickets in New York, Boston, Washington, DC, Chicago, Minneapolis, San Francisco, Los Angeles and Phoenix Now On Sale at TicketDown.com 2Health News:InSilico Medicine, Inc. Stands Out from High Tech Startups at 2015 GPU Conference 2Health News:InSilico Medicine, Inc. Stands Out from High Tech Startups at 2015 GPU Conference 3
... diabetic pregnancies have a greater risk of childhood obesity, ... Health shows breastfeeding can reduce this threat. Epidemiologist ... children of diabetic pregnancies and 399 of non-diabetic pregnancies ... of breastfeeding on the growth of body mass index ...
... News) -- Middle-school kids who participate in lots of sports ... research finds. Yet, students with teammates who smoke are ... is more pronounced among girls. "This result suggests that ... even though there might be a protective effect overall of ...
... FRANCISCO There is growing evidence that supports an association between ... thigh bone, typically without trauma and the use of ... incidence caused by osteoporosis. While the risk for suffering an ... just 1 in 1,000 patients after six years of ...
... 7, 2012). Researchers at Virginia Commonwealth University Medical ... Young Neurosurgical Center (Richmond, VA) and Old Dominion ... Wilms tumor 1 protein (WT1) results in downregulation ... lines and reduces the characteristic invasiveness exhibited by ...
... MONDAY, Feb. 6 (HealthDay News) -- ,When it comes ... of defense is lifestyle changes such as losing weight and ... get blood sugar levels under control, the American College of ... treatment that should be given. If metformin alone ...
... forests, fields, rivers -- and thereby on humans that breathe, ... comprehensive comparison of computer-based simulations from all over the world ... from ecosystems to agriculture to water supplies and health will ... be provided by more than two dozen research groups from ...
Cached Medicine News:Health News:Breastfeeding can reduce risk of childhood obesity 2Health News:Halting bone-building osteoporosis drug use cuts risk for additional atypical femur fracture in half 2Health News:CD97 gene expression and function correlate with WT1 protein expression and glioma invasiveness 2Health News:CD97 gene expression and function correlate with WT1 protein expression and glioma invasiveness 3Health News:Metformin Preferred Drug for Type 2 Diabetes, Experts Say 2Health News:Metformin Preferred Drug for Type 2 Diabetes, Experts Say 3Health News:Quantifying climate impacts: New comprehensive model comparison launched 2Health News:Quantifying climate impacts: New comprehensive model comparison launched 3
CCR Medical fiberoptic green system laryngoscope handles., ,OUTSTANDING PERFORMANCE, QUALITY, AND PRICING MAKE OUR FIBEROPTIC SELECTION MOST ECONOMICAL....
CCR Medical conventional laryngoscopes....
CCR Medical conventional laryngoscope handles....
... The Intubating LMA™ Airway. , ... or unexpected difficult airway, the LMA Fastrach™ ... without moving the head or neck. The ... attempts. , ,Selected by emergency teams ...
Medicine Products: